BridgeBio has vaulted over the success bar it set for a phase 3 rare disease trial, linking the candidate to significant improvements on biomarker and clinical outcomes to tee up a filing for FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback